Stock Analiz

Park Ha Biological Technology Co., Ltd. BYAH

Package Goods/Cosmetics · IPO 2024 · data as of November 13, 2026

$1.45Market cap $5M
Open the interactive analysis →

Park Ha Biological Technology Co., Ltd. (BYAH) is a consumer discretionary company listed in the US with a market value of about $5M. In fiscal year 2025 it had revenue of $3M and net income of -$24M, a net margin of -965.0%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -60%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.

About Park Ha Biological Technology Co.

Park Ha Biological Technology Co. is listed in the US and classified in package goods/cosmetics, IPO year 2024. Revenue went from $2M in 2022 to $3M in 2025, growth of about 9.6% a year. It was profitable in 3 of the last 4 years in our data. It spends 9% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.0
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-0.1%
Shareholder yield0.0%
Intrinsic value vs. price−77%

Growth and quality

Revenue growth (1 yr)6.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-225.1%
ROIC (5-yr avg.)-60.4%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 4 years

Fiscal year2025202420232022
Revenue$3M$2M$2M$2M
Net income-$24M$478561$852042$191298
Free cash flow-$2973$874901$103861$1M
EPS (diluted)$-7.11$0.14$0.25$0.06
Net margin-965.0%20.1%34.6%10.0%
ROIC-456.9%30.4%81.5%103.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Park Ha Biological Technology Co. stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Park Ha Biological Technology Co. pay a dividend?

Not currently.

Is Park Ha Biological Technology Co. a good stock to buy?

We do not give buy or sell advice. Park Ha Biological Technology Co. scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.